Staging and classification of gestational trophoblastic disease

Bailliere's Best Practice and Research in Clinical Obstetrics and Gynaecology

Volumn 17, Issue 6, 2003, Pages 869-883

  Hancock, Barry William ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

Classification; Gestational trophoblastic disease; Gestational trophoblastic neoplasia; Staging

Indexed keywords

ANTINEOPLASTIC AGENT; CHORIONIC GONADOTROPIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; METHOTREXATE; VINCRISTINE;

CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CHORIOCARCINOMA; CLINICAL FEATURE; DISEASE CLASSIFICATION; DRUG RESPONSE; DRUG TOXICITY; FEMALE; GONADOTROPIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HYDATIDIFORM MOLE; MULTIVARIATE ANALYSIS; NOMENCLATURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SCORING SYSTEM; TREATMENT FAILURE; TROPHOBLASTIC DISEASE; TROPHOBLASTIC TUMOR;

EID: 0347022864     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6934(03)00073-7     Document Type: Review

References (31)

1. Morrow CP. Post molar trophoblastic disease: Diagnosis, management and prognosis. Clinical Obstetrics and Gynecology 1984; 27: 211-220.
2. Hancock BW & Tidy JA. Current management of molar pregnancy. Journal of Reproductive Medicine 2002; 47: 347-354.
3. FIGO Oncology Committee Report, FIGO staging for gestational trophoblastic neoplasia 2000. International Journal of Gynaecology and Obstetrics 2002; 77: 285-287.
4. Ishizuka N, Brewer JW & Hreshchyshyn MM et al. Choriocarcinoma. In Holland JF & Hreshchyshyn MM (eds), (UICC Monograph Series) 3. Berlin: Springer, 1967. Appendix I.
5. Registration Committee for Trophoblastic Disease of the Japan Society of Obstetrics and Gynaecology, Report of the Registration Committee for Trophoblastic disease. Acta Obstetricia et Gynaecologica Japonica 1982; 34: 1805-1812.
6. Song HC, Wu PC, Tong MY & Wang YO. Clinical staging. Trophoblastic Tumours Diagnosis and Treatment. Beijing: People's Health, 1981, pp 128-129.
7. Smith DB, Holden L, Newlands ES & Bagshawe KD. Correlation between clinical staging (FIGO) and prognostic groups with gestational trophoblastic disease. British Journal of Obstetrics and Gynaecology 1993; 100: 157-160.
8. Ross GT, Goldstein DP, Hertz R et al. Sequential use of methotrexate and actinomycin D in the treatment of metastatic choriocarcinoma and related trophoblastic disease in women. American Journal of Obstetrics and Gynecology 1965; 93: 223-229.
9. Hammond CB, Borchert LG, Tyrey L et al. Treatment of metastatic disease: Good and poor prognosis. American Journal of Obstetrics and Gynecology 1973; 115: 451-457.
10. Dijkema HE, Aalders JG, DeBruijn HW et al. Risk factors in gestational trophoblastic disease, and consequences for primary treatment. European Journal of Obstetrics and Gynecology and Reproductive Biology 1986; 22: 145-152.
11. Bagshawe KD. Risk and prognostic factors in trophoblastic neoplasia. Cancer 1976; 38: 1373-1385.
12. World Health Organisation. Gestational Trophoblastic Disease. WHO Technical Report Senes 692. Geneva: WHO, 1983.
13. Newlands ES. Investigation and treatment of persistent trophoblastic disease and gestational trophoblastic tumours in the UK. In Hancock BW, Newlands ES & Berkowitz RS (eds) Gestational Trophoblastic Disease. London: Chapman and Hall, 1997, pp 173-190.
14. Kohorn EI. The trophoblastic tower of Babel: Classification systems for metastatic gestational trophoblastic neoplasia. Gynecologic Oncology 1995; 56: 1373-1385.
15. Ngan HY, Lopes AD, Lauder IJ et al. An evaluation of the prognostic factors in metastatic gestational trophoblastic disease. International Journal of Gynecological Cancer 1994; 4: 36-42.
16. Lurain JR, Casanova LA, Miller DS & Rademaker AW. Prognostic factors in gestational trophoblastic tumors: A proposed new scoring system based on multivariate analysis. American Journal of Obstetrics and Gynecology 1991; 164: 611-616.
17. Dubuc-Lissoir J, Seizig S, Schlaerth JB & Morrow CP. Metastatic gestational trophoblastic disease: Comparison of prognostic classification systems. Gynecologic Oncology 1992; 45: 40-45.
18. FIGO Oncology Committee Report, International Journal of Gynaecology and Obstetrics 1992; 39: 149-150.
19. Sobin LH & Wittekind C. TNM Classification of Malignant Tumours. New York: Wiley-Liss, 1997.
20. Goldstein DP, Zanten-Przybysz IV, Bernstein MR & Berkowitz RS. Revised FIGO staging system for gestational trophoblastic tumors. Journal of Reproductive Medicine 1998; 43: 37-43.
21. Ma HK, Wong LC & Ngan H. Staging and classification systems. In Hancock BW, Newlands ES & Berkowitz RS (eds) Gestational Trophoblastic Disease. London: Chapman and Hall, 1997, pp 95-108.
22. Soper JT, Evans AC, Conway MR et al. Evaluation of prognostic factors and staging in gestational trophoblastic tumors. Obstetrics and Gynecology 1994; 84: 969-973.
23. Azab MB, Pejovic MH, Theodore C et al. Prognostic factors in gestational trophoblastic tumors. Cancer 1988; 62: 585-592.
24. Lurain JR & Elfstrand EP. Single-agent methotrexate chemotherapy for the treatment of non-metastatic gestational trophoblastic tumors. American Journal of Obstetrics and Gynecology 1995; 172: 574-579.
25. Roberts JP & Lurain JR. Treatment of low-risk metastatic gestational trophoblastic tumors with single-agent chemotherapy. American Journal of Obstetrics and Gynecology 1996; 174: 1917-1923.
26. Soper JT, Clarke-Pearson DL, Berchuck A et al. Five-day methotrexate for women with metastatic gestational trophoblastic disease. Gynecologic Oncology 1994; 54: 76-79.
27. Bower M, Newlands ES, Holden L et al. EMA/CO for high-risk gestational trophoblastic tumors: Results from a cohort of 272 patients. Journal of Clinical Oncology 1997; 15: 2636-2643.
28. Kim SJ, Bae SN, Kim JH et al. Effects of multiagent chemotherapy and independent risk factors in the treatment of high-risk GTT - 25 years experiences of KRI-TRD. International Journal of Obstetrics 1998; 60: S85-S96.
29. Nevin J, Silcocks P, Hancock B et al. Guidelines for the stratification of patients recruited to trials of therapy for low-risk gestational trophoblastic tumor. Gynecologic Oncology 2000; 78: 92-96.
30. Kohorn EI, Goldstein DP, Hancock BW et al. Combining the staging system of the International Federation of Gynecology and Obstetrics with the scoring system of the World Health Organization for trophoblastic neoplasia. Report of the Working Committee of the International Society for the Study of Trophoblastic Disease and the International Gynecologic Cancer Society. International Journal of Gynecological Cancer 2000; 10: 84-88.
31. Hancock BW, Welch EM, Gillespie AM & Newlands ES. A retrospective comparison of current and proposed staging and scoring systems for persistent gestational trophoblastic disease. International Journal of Gynecological Cancer 2000; 10: 318-322.